2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Neelapu, S. S., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P. J., Flinn, I. W., Farooq, U., Goy, A., McSweeney, P. A., Munoz, J., Siddiqi, T., Chavez, J. C., Herrera, A. F., Xue, A., Jiang, Y., Bot, A., Rossi, J. M., Kim, J. J., Go, W. Y., Locke, F. L. AMER SOC HEMATOLOGY. 2018

View details for DOI 10.1182/blood-2018-99-111368

View details for Web of Science ID 000454842800151